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Abstract.  Human squamous cell carcinoma cell lines 
often possess increased levels of epidermal growth fac- 
tor (EGF) receptor.  The growth of these EGF recep- 
tor-hyperproducing cells is usually inhibited by EGE 
To investigate the mechanism of EGF-mediated inhibi- 
tion of cell growth,  variants displaying alternate re- 
sponses to EGF were isolated from two squamous cell 
carcinoma lines,  NA and Ca9-22; these cell lines pos- 
sess high numbers of the EGF receptor and an am- 
plified EGF receptor (EGFR) gene.  The variants were 
isolated from NA cells after several cycles of EGF 
treatment and they have acquired EGF-dependent 
growth.  Scatchard plot analysis revealed a decreased 
level of EGF receptor in these ER variants as com- 
pared with parental  NA cells.  Southern blot analysis 
and RNA dot blot analysis demonstrated that the ER 
variants had lost the amplified EGFR gene.  One variant 
isolated from Ca9-22 cells, CER-1,  grew without being 
affected by EGE  CER-1  cells had higher numbers of 
EGF receptor than parental Ca9-22 but similar EGFR 
gene copy number.  Flow cytometric analysis indicated 
an increase in ploidy and cell volume which may give 
rise to the increase in receptor number per cell.  The 
EGF receptors on both Ca9-22 and CER-1  cells were 
autophosphorylated upon EGF exposure in a  similar 
manner  suggesting no obvious alteration in receptor 
tyrosine kinase.  However, very efficient down-regula- 
tion of the EGF receptor occurred in CER-1  cells. 
These data suggest two independent mechanisms by 
which EGF receptor-hyperproducing cells escape 
EGF-mediated growth inhibition:  one mechanism is 
common and involves the loss of the amplified EGFR 
genes, and another is novel and involves the efficient 
down-regulation of the cell-surface receptor. 
PIDERMAL growth factor (EGF) 1 is a potent mitogen 
for a variety of cells (Carpenter and Cohen,  1979). 
The mitogenic  signal of EGF is transduced through 
its membrane-anchored glycoprotein receptor of Mr 170,000 
(Cohen et al., 1982). The binding of EGF to the receptor in- 
duces a series of biochemical reactions including  autophos- 
phorylation of the EGF receptor (Cohen et al., 1980), clus- 
tering of the EGF receptor into coated pits (Schechter et al., 
1979) and internalization  and intracellular  processing of the 
EGF/EGF receptor complex (Schlessinger  et al., 1978; Hai- 
Rier et al.,  1978; Miskimins  and Shimizu,  1984).  Concur- 
rently, cellular protein phosphorylation (Hunter and Cooper, 
1981), c-fos and c-myc protooncogene expression  (Mfiller et 
al.,  1985)  and phosphatidylinositol  turnover (Sawyer and 
Cohen,  1981) are induced. 
However, the presence of EGF at the concentrations  mito- 
genic for other cells was found to be markedly inhibitory  for 
the growth of the epidermoid carcinoma cell line A431 (Gill 
and Lazar,  1981; Barnes,  1982), which possesses extremely 
high numbers of the EGF receptor (Fabricant  et al.,  1977) 
1. Abbreviations used in this paper:  EGE epidermal growth factor; EGFR, 
epidermal growth factor receptor (genes). 
as well as EGF receptor (EGFR) gene amplification  (Lin et 
al.,  1984;  Ullrich  et al.,  1984).  Similar  growth  inhibition 
has been reported for the breast cancer cell line MI3A-468 
(Filmus et al., 1987), which also possesses high numbers of 
the EGF receptor. To determine which biochemical response 
is crucial for growth  inhibition  of these cells and also for 
growth  stimulation  of cells with ordinary numbers of EGF 
receptor, we and others have isolated EGF-response variants 
using EGF (Buss et al., 1982; Bravo, 1984), EGF conjugated 
with the A subunit of ricin (Shimizu et al.,  1984) and anti- 
EGF receptor antibody conjugated  with the A subunit of ri- 
cin  (Behzadian  and  Shimizu,  1985a).  The  correlation  of 
growth inhibition  with receptor concentration  (Kawamoto et 
al.,  1984),  receptor tyrosine kinase activity (Buss  et al., 
1982), cellular protein phosphorylation (Buss et al., 1984), 
receptor metabolism (Lifshitz  et al.,  1983), protooncogene 
induction (Bravo et al., 1985) and phosphatidylinositol  turn- 
over (Behzadian and Shimizu,  1985a) was extensively stud- 
ied in these variants.  In most cases, the variants were found 
to contain  reduced levels  of EGF receptor (Filmus et al., 
1987; Buss et al., 1982; Shimizu et al., 1984; Behzadian and 
Shimizu,  1985a),  which seemed to be essential  for escape 
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ceptor numbers accompanied the loss of  the amplified EGFR 
gene which was  responsible for receptor hyperproduction 
(Filmus et al.,  1987;  Gill et al.,  1985). 
Recently, many of the cell lines derived from squamous 
cell carcinoma of the head and neck (Cowley et al.,  1984) 
and the oral cavity and esophagus (Yamamoto et al.,  1986; 
Gamou et al., 1988) were reported to possess elevated levels 
of  EGF  receptor  accompanied  with  EGFR  gene  am- 
plification. 
In this report, we describe that EGF-mediated growth inhi- 
bition  is  common  in  EGF  receptor-hyperproducing cell 
lines. Further, variants which displayed alternate responses 
to EGF were isolated from two squamous cell carcinoma cell 
lines,  NA and Ca9-22.  Our analysis of the EGF-response 
variants suggested a novel mechanism by which EGF recep- 
tor-hyperproducing cells escape EGF-mediated growth inhi- 
bition without losing the amplified EGFR gene. 
Materials and Methods 
Cell Culture 
Squamous cell carcinoma cell lines (Yamamoto et al., 1986; Gamou et al., 
1988) were kindly provided by Dr. K. Rikimaru (Tokyo Medical and Dental 
University, Tokyo,  Japan).  Cell  lines were maintained in DME  (Gibeo, 
Grand Island, NY) supplemented with 10% FCS (Boehringer-Mannheim), 
kanamycin  (100  ~tg/ml,  Meiji,  Tokyo,  Japan)  and  fungizone  (1  [.tg/ml, 
Squibb, Princeton, NJ) (DME/FCS10) in 5% CO2 and 100% humidity at 
37°C. 
Variant Selection 
NA and Ca9-22  cells grown in a  90-mm culture dish (',d07 cells/dish) 
were treated with EGF (100 ng/ml; Toyobo [Osaka, Japan]; ultra pure grade) 
for 3 d and then transferred to 10 90-mm dishes. Fresh media containing 
EGF (100 ng/ml) were added every 3 d for 1 too. Several independent colo- 
nies which grew in the presence of EGF were isolated. To determine the 
growth rate of the cells, 5  ×  l04 cells were plated in 35-ram culture dishes 
containing DME/FCS10. After 24 h of incubation, the media was replaced 
with  media containing various  concentrations of EGE  The  cells  were 
detached with trypsin/EDTA and counted with a hemocytometer. 
p2Jl]EGF-binding Assay 
[~251]EGF Binding was assayed as previously described (Gamou  et  al., 
1984).  To separate cell surface-bound EGF from intracellular EGE cells 
which had been incubated with [~25I]EGF were treated for 1 min with 0.5 
M NaCI/0.2 N acetic acid as described (Haigler et al., 1980). Then the cells 
were dissolved with 1 N  NaOH to determine the amount of intracellular 
EGE Degraded EGF in the conditioned medium was separated from intact 
EGF by adding TCA (final concentration 20%) as described (Gamou et al., 
1984). 
EGF-Receptor Gene and Its Expression 
DNA was isolated as previously described (Hunts et al., 1985), and digested 
with Hind III (Toyobo).  The restriction fragments were separated by aga- 
rose gel (0.8%)  electrophoresis and transferred to  a  nitrocellulose filter 
(Schleicher &  Schiill, Keene, NH). 
RNA dot blot hybridization was carried out as described (White and Ban- 
croft, 1982).  Briefly,  cells in 45 p.I of Tris buffer (10 mM, pH 7.0)/EDTA 
(1 mM) were lysed by adding 5 p.I of 5% Triton X-100 and mixing on ice 
for 5 min. After a brief centrifugation to pellet the nuclei, 50 p.l of superna- 
tant was mixed with 30 p.l of20x SSC and 20 lal of formalin and incubated 
at 60oc for 15 min. The cell extract was serially diluted with 15× SSC and 
applied to a  nitrocellulose filter. 
The EGF receptor eDNA pE7 (Merlino et al.,  1984),  kindly provided 
by Dr.  I.  Pastan (National Cancer Institute, Bethesda, MD), was labeled 
with [ot-32P]dCTP and used as a hybridization probe as described (Hunts 
et al.,  1985). 
Flow Cytometric  Analysis of  Cell Volume 
and EGF Receptor 
Cell volume was determined by the intensity of forward scatter light (Mul- 
laney and Dean,  1970) using Toraysphere (Toray  Techno Co. Ltd., Otsu, 
Japan) as a size marker. 
To measure the EGF receptor density on the cell surface, cells were first 
incubated with anti-human EGF receptor monoclonal antibody B4G7 (Beh- 
zadian and Shimizu, 1985b) for 40 min at 0oc in DME buffered with Hepes 
(25 mM, pH 7.4),  and washed twice with PBS supplemented with glucose 
(1  mg/ml). Then the cells were incubated with FITC-iabeled sheep anti- 
mouse lgG antibody (Silenus), washed as described above and resuspended 
in Hepes-buffered DME. A FACS 440 (Becton Dickinson) was used for the 
flow cytometric analysis (Maron et al.,  1984). 
Quantitation of  CeUular DNA Content 
Detached cells were fixed with 70% ethanol, washed twice with glucose- 
supplemented PBS and treated with RNase A (1 mg/ml, Sigma Chemical 
Co., St. Louis, MO) for 30 rain at 37°C. Then the cells were washed twice 
with calcium- and  magnesium-free PBS  containing EDTA  (0.02%)  and 
stained with propidium iodide (50 ~tg/ml) in the same solution. Flow cyto- 
metric analysis was performed as described (Crissman and  Steinkamp, 
1973). 
Chromosome Analysis 
Chromosome spreads were prepared after 0.075 M KCI treatment and Car- 
noy fixation. Karyotypes were analyzed after trypsin/Giemsa banding as de- 
scribed (Gill  et al.,  1985). 
Rate of  Receptor Biosynthesis 
4  x  105 cells were plated in 35-ram dishes and incubated at 37°C for 2 d. 
Cells were treated with EGF (100 ng/ml) for the indicated times, washed 
twice with methionine-free  DME (Microbiological Assoc.) and then labeled 
with [35S]methionine  (80 p,  Ci/ml, tran-35S-label,  ICN) in methionine-free 
DME/FCSI0 for 30 min. After labeling, the EGF receptor was immunopre- 
cipitated with IMG7 antibody bound to protein A-Sepharose and analyzed 
on SDS-PAGE as described previously (Gamou et al.,  1987). 
Receptor Phosphorylation 
Confluent cells in 35-mm dishes were washed twice with phosphate-free 
minimum essential  medium  (MEM),  then  labeled with  [32p]orthophos- 
phate (2.5 mCi/ml, Amersham Corp., Arlington Heights, IL) in phosphate- 
free MEM for 1 h. EGF (200 ng/ml) was directly added to medium at 15 
min before lysis. After labeling, the EGF receptors were immunoprecipi- 
tated with B4G7 and purified on SDS-PAGE as described before (Gamou 
et  al.,  1987).  Two-dimensional  phosphopeptide  mapping  and  phos- 
phoamino acid analysis were performed as described previously (Beemon 
and Hunter,  1978, Iwashita and Fox,  1984). 
Results 
Isolation of  EGF Resistant Variants 
Growth of the EGF receptor-hyperproducing A431  epider- 
moid carcinoma cell line was inhibited by EGE Overproduc- 
tion of EGF receptor to the same extent as A431  cells was 
often observed in squamous cell carcinoma lines (Yamamoto 
et al.,  1986; Gamou et al.,  1988). Thus, we first examined 
whether EGF-mediated growth inhibition is common in these 
EGF receptor-hyperproducing cell lines. As shown in Fig. 
1, EGF inhibited the growth of the receptor-hyperproducing 
cell lines. 
To investigate the mechanism of EGF-mediated inhibition 
of cell growth, variants showing alternate responses to EGF 
were isolated from two cell lines, NA and Ca9-22. These cell 
lines have a high number of EGF receptors (Table I) and an 
amplified EGFR gene; they are the most sensitive cell lines 
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l~gure 1. EGF-mediated growth  ~0, 
inhibition  in  EGF  receptor- 
hyperproducing cell  lines.  5 
-~ to  3  x  104 cells  of each cell  line 
were plated  in 35-mm dishes  .~ 
o 
and  incubated  for  1 w.  EGF  -  , 
was added at various concen-  ., 
trations on 1, 3, and 5 d. Cells  o_ 
were  detached  with  trypsin/  ~ 101 
EDTA  and  counted  on  7  d 
using  a  hemocytometer.  (a) 
NA; (n) Ca9-22; (o) HSC-2;  1o* 
(o)  HSC-3;  (v)  HSC-4;  (~7) 
A431. 
to EGF-mediated growth inhibition. Variants which grew af- 
ter several cycles of EGF (100 ng/ml) treatment appeared at 
an approximate rate of 1  ×  10  -6 in both cell lines, and sev- 
eral clones were isolated from each cell line. 
Characteristics of  EGF-Resistant Variants 
from NA Cells 
As shown in Fig. 2 A and B, the ER variants, from NA cells, 
grew in an EGF dose-dependent fashion.  The ER variants 
and parental NA cells showed no difference in their morphol- 
ogy while growing (Fig. 3, A and D). Scatchard plot analysis 
revealed a decreased level of EGF receptors on their surface 
as compared with NA cells (Table I). Autophosphorylation 
of the EGF receptor from membrane preparation indicated 
a substantial decrease in EGF-responsive protein kinase ac- 
tivity (data not shown), reflecting the decrease in active EGF 
receptor on their surface. 
To examine the reason for the reduced levels of EGF recep- 
tor on the cell surface, Southern blot analysis and RNA dot 
hybridization analysis were performed using the EGF recep- 
tor cDNA probe pE7.  The ER variants were found to have 
lost their amplified EGFR gene (Fig. 4 A), accompanied by 
a  decrease in EGF receptor mRNA (Fig.  4  B). 
Thus, the mechanism to acquire resistance to EGF-medi- 
ated growth inhibition in these variants appears to be through 
a decrease in EGF receptor level by the loss of the amplified 
EGFR gene.  This  situation  is  similar to the EGF-resistant 
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Figure 2.  Growth of the ER variants  in the presence of EGF.  (A) 
EGF dose-response study. 5  x  104 cells were incubated  with vari- 
ous concentrations of EGE  After  1 w  of incubation,  cells  were 
detached  and counted as described in Fig.  1. (A) NA; (o) ER6-7; 
(ix) ERll. (B) Kinetic  study. ERll  (5  ×  104 cells)  was incubated 
in the absence (zx) or presence (A) of EGF (50 ng/ml).  EGF was 
added on 1, 3, 5, and 7 d. Cells were detached and counted on every 
other day as described in Fig.  1. 
variants isolated from A431 cells (Gill et al.,  1985).  How- 
ever, the ER variants are unique because of their acquired 
EGF-dependent growth. In contrast, the variants from A431 
cells previously reported grew regardless of the presence or 
absence of EGF (Buss et al.,  1982). 
Characteristics of  EGF-Resistant Variants 
from Ca9-22 Cells 
The CER variants  were  isolated  from Ca9-22  cells  in the 
same manner that ER variants were isolated from NA cells. 
The CER variants in general appeared to have a flatter mor- 
phology than the parental cells (Fig.  3, E  and G).  Many of 
the variants grew regardless  of the presence of EGF but at 
retarded rate (Fig. 5). EGF resistance was further analyzed 
in CER-1 cells,  the only variant which grew without being 
affected by EGF. 
Scatchard plot analysis revealed higher numbers of EGF 
receptor in CER-1 cells than in Ca9-22 cells (Table I). Flow 
cytometric analysis using anti-EGF receptor antibody also 
demonstrated the increased EGF receptor level on the CER-1 
cell  surface  (~150%  of Ca9-22,  Fig.  6  A).  Cytoplasmic 
Table I. EGF Receptor Number and Affinity in EGF-Response Variants 
Receptor Number  Dissociation Constant 
Cell  High*  Low*  Total  Kd~  I~  2 
×  105 sites~cell  nM  nM 
NA  6  41  47  0.4  8.3 
ER6-7  0.4  2.6  3  0.25  16 
ER11  0.5  2.5  3  0.25  13 
Ca9-22  3  21  24  0.3  7.0 
Ca9-22  (EGF)~;  ND  21  21(13%)§  ND  7.0 
CER-1  4  47  51  0.12  5.5 
CER-1  (EGF)*  ND  20  20(61%)§  ND  5.5 
* The number of high (K~,) and low (K¢:) affinity type EGF receptor was determined by the Scatchard plot analysis. 
~: Cells were treated with EGF (10 ng/ml) for 10 h before the [~251]EGF-binding  assay. 
§ Loss of EGF receptor number after EGF treatment. 
ND, Not detected. 
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hyperproducing cells and their variants. (A 
and B), NA cells; (Cand D), ERll cells; (E 
and F),  Ca9-22 cells;  (G and H),  CER-1 
cells. (.4, C, E, and G), cultures in the ab- 
sence of EGF, (B, D, F, and H), in the pres- 
ence of EGF (100  ng/ml) for 24 h. Bar, 10 ~tm. 
RNA dot blot analysis indicated a relatively higher level of 
EGFR gene expression in CER-I cells (Fig. 7 B). Southern 
blot analysis, however, did not indicate an increased amount 
of EGFR gene (Fig. 7 A). No difference on the rate of recep~ 
tor protein biosynthesis was observed in CER-1  cells com- 
pared to Ca9-22 cells (Fig.  8). 
Interestingly,  cytogenetic analysis and flow cytometric anal- 
ysis for DNA content indicated an increase in the ploidy of 
CER-1  cells. Ca9-22 cells are hyperdiploid (mode of chro- 
mosome number,  56-57)  (Fig.  9  A)  with numerous rear- 
ranged chromosomes (Fig.  10),  whereas CER-1  cells were 
hypertriploid (mode of chromosome number, 83) (Fig. 9 A). 
Flow cytometric analysis confirmed the presence of a larger 
amount of DNA in CER-1 cells than in Ca9-22 (Fig. 9, B and 
C). Thus, the increase in ploidy could result in an increase 
in cell volume (and cell surface) in CER-1 cells, which may 
accompany the  increase  in  receptor number per  cell.  As 
shown in Fig. 6 B, flow cytometric analysis demonstrated an 
increased cell volume in CER-1  cells (,,o116% of Ca9-22). 
EGF Receptor Phosphorylation 
We have examined the possibility whether the acquired EGF 
resistance in  CER-!  cells correlates with a  change  in  the 
EGF receptor autophosphorylation. As shown in Fig.  11 A, 
EGF receptors in both CER-1 and Ca9-22 cells were phos- 
phorylated and their phosphorylation was enhanced by EGE 
Phosphopeptide map  showed that  the  phosphorylation of 
peptide 9  was  enhanced by EGF (Fig.  11  B).  The phos- 
phorylated amino acid of this peptide was found to be tyro- 
sine (data not shown). Considering the previous observation 
for A431 cells (Downward et al., 1984), this peptide is likely 
to correspond to the in vivo autophosphorylation site includ- 
ing  the  Tyr-l173 residue.  Thus,  EGF receptors in  CER-1 
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(10 I.tg) was digested  with Hind III, serially diluted,  subjected  to 
electrophoresis on an agarose gel (0.8%) and transferred  to a nitro- 
cellulose filter.  106 cells  were lysed with  Triton X-100 containing 
buffer and centrifuged briefly to separate  cytoplasmic and nuclear 
fractions.  Cytoplasmic fractions,  containing RNA, were denatured 
with formalin,  serially  diluted with 15x SSC and applied  directly 
to a nitrocellulose  filter equilibrated  with 15× SSC. Hybridization 
was  performed  using  the  EGF  receptor cDNA probe  pE7.  (A) 
Southern blot analysis.  (Lane 1) NA (10 ~tg); (lane 2) NA (5 ~tg); 
(lane 3) NA (2.5 ~tg); (lane  4) NA (1.25 ~tg); (lane 5) ERII (10 
Itg); (lane 6) placenta (10 ~tg). Size marker used was lambda phage 
DNA cut with Hind III. (B) RNA dot blot hybridization analysis. 
(Lane 1 ) NA; (lane 2) ER11 maintained  in the absence of EGF for 
2d. 
cells can be autophosphorylated in a  manner similar to pa- 
rental Ca9-22 cells.  These results suggest that alterations in 
EGF receptor kinase may not be involved in the EGF resis- 
tance in CER-1 cells. 
EGF Internalization and Receptor Down-Regulation 
We have examined the possible difference in the internaliza- 
tion and degradation rate of EGF in CER-1 and Ca9-22 cells 
at  37°C.  As  shown  in  Fig.  12,  A  and  B,  the  amount  of 
[~25I]EGF associated with the intracellular fraction and mem- 
---It  •  , " 
A.  =1.. 
e 
%  "01   i  t: 
xa~us-I) 
•  •  o  .  .  •  • 
B. 
lOd  F 
i  / 
1 ,oO  IY  "/ 
1 
iod.  i  "  i  "  i" 
(days) 
Figure 5. Growth of the CER variants in the presence of EGE EGF 
dose-response study and kinetic study were carried out as described 
in Fig.  2. (A) EGF dose-response study.  (A) Ca9-22; (o) CER-I; 
(zx) CER-4; (t~) CER-8.  (B) Kinetic  study.  (zx) CER-1 in the ab- 
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Figure 6.  Flow cytometric analysis  of relative  number of EGF 
receptors  and cell volume in Ca9-22 and CER-1. Cells  were in- 
cubated with anti-EGF receptor antibody (IMG'/) for40 min at 4°C 
and then with FITC-conjugated secondary antibody.  Analysis was 
performed on a FACS 440. To determine nonspecific binding of an- 
tibodies,  cells were first incubated  with a nonspecific  mouse IgG 
and then with the secondary antibody.  (,4) Logarithm of fluores- 
cence intensity. The solid line (  ) and dotted line ( ....... ) indi- 
cate the IMG7 derived fluorescence  in Ca9-22 and CER-1, respec- 
tively. The broken line (-----) and sparsely dotted  line ( .... ) 
indicate  nonspecific  fluorescence in Ca9-22 and CER-1,  respec- 
tively. (B) Forward scatter light intensity. The solid line and dotted 
line indicate the intensity of the forward scatter light of Ca9-22 and 
CER-I, respectively. 
brahe fraction of CER-1  cells was lower than Ca9-22 cells 
despite  the  elevated  EGF  receptor  levels.  Moreover,  there 
was no difference in the secretion rate of  degraded EGF (Fig. 
12  C).  Then,  we examined  the  ['2SI]EGF-binding activity 
after cells were treated  with unlabeled EGF (10 ng/ml) for 
various periods  of time.  EGF-binding activity of both cell 
lines was reduced within 3 h to a similar level and the reduced 
level was kept for at least  10 h  (data not shown).  Scatchard 
plot analysis of the binding data revealed that Ca9-22 cells 
lost 13 % of the total EGF receptors by EGF exposure, where- 
as CER-1 cells lost 61% of the initial surface receptors (Table 
Hirai et al. EGF Receptor Variants  795 Figure  7.  EGFR gene  and  its expression  in Ca9-22  and CER-I. 
DNA and RNA were prepared and the hybridization was performed 
as described in Fig. 4. (A) Southern blot analysis and (B) RNA dot 
blot hybridization analysis. (Lane 1 ) Ca9-22; (lane 2) CER-1 main- 
rained in the presence of EGF; (lane 3)  in the absence of EGF. 
I). The decreased EGF binding after exposure to a  limited 
amount of EGF suggests efficient down-regulation of the re- 
ceptor. Since EGF receptor gene expression was not affected 
by EGF (Figs. 7 B and 8), the down-regulation may not be 
caused  by  transcriptional  or  translational  control.  If the 
receptor internalization occurs only with bound EGF, CER-1 
cells with elevated number of receptors should have more in- 
ternalized EGF than Ca9-22 cells. However, this was not the 
case. The receptors internalized from CER-1 cells after EGF 
exposure  were  far  more  than  the  number  expected  from 
EGF-binding  assay.  Therefore,  these  results  suggest  that 
CER-1  cells down-regulate (or internalize)  the unoccupied 
surface receptors  more efficiently than  Ca9-22  cells.  The 
down-regulation seen in CER-1  cells may involve a mecha- 
nism similar to the negative cooperativity or desensitization 
of  the  hormone  receptor.  Although  the  exact  molecular 
mechanism must await further investigation, this mechanism 
may give rise to the EGF-resistance of CER-1  cells without 
loss of the amplified EGF receptor gene. 
Figure  8.  EGF receptor  bio- 
synthesis in Ca9-22 and CER- 
1. Cells were treated with EGF 
(100 ng/ml) for the indicated 
times,  labeled  with  [35S]me- 
thionine  (80  ~tCi/ml) for  30 
min and lysed with RIPA  buf- 
fer. EGF receptor was immu- 
noprecipitated using anti-EGF 
receptor antibody and subjected 
to  electrophoresis  on  SDS- 
polyacrylamide gel (7%), fol- 
lowed by fluorography  (A). The 
radioactivity in EGF receptor 
region  was  determined  in  a 
liquid  scintillation  counter 
(Beckman LS3800) after sol- 
ubilizing  the  gel  with  15% 
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Figure  9.  Chromosome num- 
ber and DNA content in Ca9- 
22 and  CER-I.  (A) Chromo- 
some number analysis. Chro- 
mosome spreads were prepared 
after treatment  with 0.075 M 
KCI and Carnoy  fixative and 
stained with Giemsa solution. 
76 and 74 metaphases of Ca9- 
22  and  CER-I,  respectively, 
were photographed and chro- 
mosome  number  was  deter- 
mined. The solid line and dot- 
ted line represent Ca9-22 and 
CER-1 cells, respectively. (B) 
Flow  cytometric  analysis  of 
DNA content in Ca9-22. Ca9- 
22 cells were fixed with 70% 
ethanol, treated with RNase A 
and  stained  with  propidium 
iodide (50 I.tg/ml). Flow cyto- 
metric analysis was performed 
on a FACS 440. (C) Flow cy- 
tometric analysis of DNA con- 
tent in CER-1. 
Discussion 
Addition  of EGF to the  culture medium at concentrations 
that are mitogenic for other cell types results in a marked iu- 
hibition of A431 cells' growth (Gill and Lazar, 1981; Barnes, 
1982).  We extended  this  analysis  to  other  EGF  receptor- 
hyperproducing cell lines of squamous cell carcinoma origin 
(Yamamoto et al., 1986; Gamou et al., 1988). We found that 
growth  inhibition  by  EGF  is  common  in  EGF  receptor- 
hyperproducing cell  lines.  The only exception is the pan- 
creatic carcinoma cell line UCVA-1, possessing ~9  ×  105 
receptors/cell (Gamou et al., 1984) with no EGFR gene am- 
plification (Hunts et al.,  1986). The growth of UCVA-1 cells 
was not affected by EGF under either serum-free or serum- 
containing conditions. UCVA-1 cells have a decreased rate of 
metabolic turnover of the EGF receptor, which may be re- 
sponsible for the increased cell surface receptor level (Gamou 
and Shimizu,  1987).  This novel mechanism, however, may 
not cause EGF-resistance, since the turnover rate in the pres- 
ence of EGF was similar to other EGF-sensitive, receptor- 
hyperproducing cell lines. 
To investigate the mechanism of EGF-mediated growth in- 
hibition as  well  as  EGF-mediated growth  stimulation,  we 
The Journal  of Cell  Biology,  Volume  107,  1988  796 Figure 10.  Karyotype of Ca9-22.  The chromosome spread was prepared as described in Fig.  9. Karyotype analysis was carried out after 
G-band staining.  Arrows indicate the rearranged chromosomes. 
and  others  have  isolated  variants  displaying  alternate  re- 
sponses  to  EGF  (Filmus  et  al.,  1987;  Buss  et  al.,  1982; 
Bravo,  1984; Shimizu et aI.,  1984; Behzadian and Shimizu, 
1985a).  In this  report,  we described  two series of variants 
with altered responses to EGF derived from the receptor-hy- 
perproducing cell lines, NA and Ca9-22. Our results suggest 
two  independent  mechanisms by which  the variants escape 
EGF-mediated growth inhibition.  One mechanism is the loss 
of the amplified EGFR gene responsible for EGF receptor- 
hyperproduction  as demonstrated  by the ER variants.  This 
type of variant has also been isolated  from the epidermoid 
carcinoma cell line A431  (Gill et al.,  1985)  and the breast 
Figure 11.  EGF receptor phosphorylation in Ca9- 
22 cells and CER-I cells.  (A) Cells were labeled 
with  [32p]orthophosphate  for 60 min and treated 
with EGF (200 ng/ml) for the last 15 min. Immu- 
noprecipitated  EGF receptors were separated on 
SDS-polyacrylamide gel (7%), followed by auto- 
radiography. (B) EGF receptors were eluted from 
gel  and  digested  with  TPCK-trypsin (50  ~tg) at 
37°C for 24 h. The digests were separated on thin 
layer plates (20  x  20 cm): (1st) electrophoresis at 
pH 8.9 in 1% ammonium bicarbonate; (2nd) chro- 
matography in butanol/pyridine/acetic acid/water 
(15:10:3:12,  voi/vol).  32P-labeled  Peptides  were 
identified  by autoradiography for which exposure 
time was adjusted to keep cpm ×  day values con- 
stant. The radioactivities loaded on the gels were: 
(a,  1,814 cpm), (b, 4,653 cpm), (c, 300 cpm), (d, 
1,193 cpm).  (a  and  b)  Ca9-22  cells;  (c and  d) 
CER-1  cells; (a and c) no EGF stimulation; (b and d) after EGF stimulation;  (e) a diagram of tryptic phosphopeptides:  phosphorylated 
amino acids contained in each spot were as follows:  (1) Serine; (2) Threonine>Serine,  Tyrosine; (3) Serine;  (4) threonine;  (5) Serine; 
(6) Threonine>Serine;  (7)  Serine;  (8) Serine,  (9) Tyrosine. 
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Figure 12. Internalization and degradation of EGF by Ca9-22 and 
CER-1. Cells were incubated with [t2SI]EGF (100 ng/ml,  3,600 
cpm/ng) at 37°C for the indicated times, placed on ice and treated 
with 0.2 M acetic acid/0.5 N NaCI for 1 min to remove the cell sur- 
face fraction of cell-associated [t2SI]EGF (B). Then, the cells were 
dissolved in 1 N NaOH to determine the intracellular fraction (A). 
The conditioned medium was collected from each culture. TCA was 
added to the media (final concentration 20%) to separate degraded 
EGF (TCA soluble fraction) (C) from intact EGF. (o) Ca9-22; (o) 
CER-1. 
cancer cell line MDA-468 (Filmus et al.,  1987). Resistance 
of  these cells was reported to be stable in the absence of EGF 
for a long period, and seemed to arise from the loss of a cer- 
tain rearranged chromosome carrying the amplified EGFR 
gene (Gill et al.,  1985). Cytogenetic analysis revealed that 
the ER variants commonly lost a certain rearranged chromo- 
some seen in NA cells (Gamou, S., M. Kobayashi, and N. 
Shimizu, unpublished observation). Thus, the examination 
of whether the amplified EGFR gene is mapped on the rear- 
ranged chromosome may be interesting. 
The ER variants grew in a strictly EGF-dependent manner. 
Although the growth of A431  variants was  reported to be 
stimulated by EGF (Buss et al., 1982), they could also grow 
in the absence of EGF. ER cells showed a flat morphology 
in the absence of EGF as if they were in the resting stage. 
We have not been able to identify the molecular basis for the 
difference in response to EGF in these cells. 
Another unique variant, CER-1 cells, acquired EGF-resis- 
tance without the loss of the amplified EGFR gene or recep- 
tor kinase activity. This type of variant has not been previ- 
ously described. In contrast to other variants (Filmus et al., 
1987;  Gill et al.,  1985),  CER-1  cells gradually regain the 
sensitivity to EGF-mediated growth inhibition if they are 
kept in the absence of EGF for several mo. 
We described several characteristics that may be related to 
the mechanism of EGF-resistance in CER-1 cells. One is the 
increased cell volume and ploidy. This may allow escape 
from the growth inhibition by EGF although the relationship 
of increased cell volume and ploidy to EGF-resistance re- 
mains to be elucidated. 
Another distinction between CER-1  and parental Ca9-22 
cells is  the efficient EGF receptor down-regulation which 
is disjoined from EGF internalization in the variant.  This 
seemed to include receptor desensitization to the ligand. The 
mechanism of down-regulation reduced the EGF receptor 
level on the cell surface emulating a loss of the amplified 
EGFR gene. Thus, this down-regulation may play an impor- 
tant role in uncoupling the excess signals by EGF from the 
cellular responses. 
We  previously  isolated  variants  from  Swiss-3T3  cells 
using insulin conjugated with diphtheria toxin A  fragment 
(Miskimins and Shimizu,  1981). One of these variants re- 
tained the ability to bind insulin, but accumulated lysosome- 
like vesicles in their cytoplasm, suggesting an alternative en- 
docytic pathway involved in escaping the cytotoxicity of the 
chimeric insulin (Miskimins et al., 1981). The alternative en- 
docytic pathway does not appear to be a factor in the present 
situation because excess accumulation of EGF was not ob- 
served in the intracellular fraction of CER-1  cells. 
As described above, exclusion of the amplified EGFR gene 
seems to be the most common mechanism to reduce the EGF 
receptor level on the cell surface. CER-1  cells may use the 
down-regulation mechanism instead of losing their EGFR 
genes because of the possibility that their EGFR genes are 
rearranged and tightly linked with some gene(s) essential for 
Ca9-22 cells to survive in vitro. In fact, our karyotype analy- 
sis revealed numerous rearranged chromosomes but no in- 
tact chromosome 7. 
Although the exact mechanism of EGF-resistance remains 
to be elucidated, these variants will be useful to investigate 
not only the physiological function of EGF and its receptor, 
but also the genetic and epigenetic control of EGFR gene 
expression. 
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